



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Inventors:**

Kuhn-Wache, Kerstin et al.

**Application No.:**

10/667,200

**Attorney Docket No.:**

PBD-00027 (formerly 20488/57)

**Filed:**

9/18/2003

**Group Art No.:**

1614

**Examiner:**

Not Known

**Title:**Secondary Binding Site of Dipeptidyl  
Peptidase IV (DPIV).

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Mail Stop Missing Parts**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

OSI Pharmaceuticals, Inc.

By

Alexander A. Stewart

Date

4/13/05

Mail Stop Missing Parts,  
Commissioner for Patents,  
P.O. Box 1450, Alexandria, VA 22313-1450

Applicants respectfully submit the following:

- 1) Amendment and Response, including Sequence Listing (both paper copy and computer-readable forms), and a Statement In Accordance with 37 C.F.R §1.821(f).
- 2) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.
- 3) Return receipt postcard.

Sir:

04/18/2005 HELAND 00000002 502783 10667200  
A. FORTIN 025.00 DA

**AMENDMENT AND RESPONSE**

In response to a Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures issued by

the U.S. Patent and Trademark Office on December 13, 2004 in connection with the above-identified application, Applicants respectfully petition for a two month extension of the deadline to respond, to April 13, 2005. The Examiner is authorized to charge \$450.00 in accordance with 37 CFR 1.17(a)(3), and any deficiencies in fees, and credit any overpayment to OSI Pharmaceuticals, Inc. Deposit Account No. 50-2783. Applicants respectfully request entry of the following amendments:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Amendments to the Specification** begin on page 11 of this paper.

**Remarks** begin on page 20 of this paper.